Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells

Silvia Dragoni, Marta Reforgiato, Estella Zuccolo, Valentina Poletto, Francesco Lodola, Federico Alessandro Ruffinatti, Elisa Bonetti, Germano Guerra, Giovanni Barosi, Vittorio Rosti, Francesco Moccia

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Endothelial progenitor cells could be implicated in the aberrant neoangiogenesis that occurs in bone marrow and spleen in patients with primary myelofibrosis (PMF). However, antivascular endothelial growth factor (VEGF) monotherapy had only a modest and transient effect in these individuals. Recently it was found that VEGF-induced proangiogenic intracellular Ca2+ oscillations could be impaired in endothelial progenitor cells of subjects with malignancies. Therefore, we employed Ca2+ imaging, wavelet analysis, and functional assays to assess whether and how VEGF-induced Ca2+ oscillations are altered in PMF-derived endothelial progenitor cells. We focused on endothelial colony-forming cells (ECFCs), which are the only endothelial progenitor cell subtype capable of forming neovessels both in vivo and in vitro. VEGF triggers repetitive Ca2+ spikes in both normal ECFCs (N-ECFCs) and ECFCs obtained from PMF patients (PMF-ECFCs). However, the spiking response to VEGF is significantly weaker in PMF-ECFCs. VEGF-elicited Ca2+ oscillations are patterned by the interaction between inositol-1,4,5-trisphosphate-dependent Ca2+ mobilization and store-operated Ca2+ entry. However, in most PMF-ECFCs, Ca2+ oscillations are triggered by a store-independent Ca2+ entry pathway. We found that diacylglycerol gates transient receptor potential canonical 1 channel to trigger VEGF-dependent Ca2+ spikes by recruiting the phospholipase C/inositol-1,4,5-trisphosphate signaling pathway, reflected as a decrease in endoplasmic reticulum Ca2+ content. Finally, we found that, apart from being less robust and dysregulated as compared with N-ECFCs, VEGF-induced Ca2+ oscillations modestly stimulate PMF-ECFC growth and in vitro angiogenesis. These results may explain the modest effect of anti-VEGF therapies in PMF.

Original languageEnglish
JournalExperimental Hematology
DOIs
Publication statusAccepted/In press - May 19 2015

Fingerprint

Primary Myelofibrosis
Vascular Endothelial Growth Factor A
Inositol 1,4,5-Trisphosphate
Endothelial Growth Factors
Wavelet Analysis
Diglycerides
Type C Phospholipases
Endoplasmic Reticulum
Spleen
Endothelial Cells
Bone Marrow
Endothelial Progenitor Cells

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. / Dragoni, Silvia; Reforgiato, Marta; Zuccolo, Estella; Poletto, Valentina; Lodola, Francesco; Ruffinatti, Federico Alessandro; Bonetti, Elisa; Guerra, Germano; Barosi, Giovanni; Rosti, Vittorio; Moccia, Francesco.

In: Experimental Hematology, 19.05.2015.

Research output: Contribution to journalArticle

Dragoni, Silvia ; Reforgiato, Marta ; Zuccolo, Estella ; Poletto, Valentina ; Lodola, Francesco ; Ruffinatti, Federico Alessandro ; Bonetti, Elisa ; Guerra, Germano ; Barosi, Giovanni ; Rosti, Vittorio ; Moccia, Francesco. / Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells. In: Experimental Hematology. 2015.
@article{671b8d6e30ff4b18b50dad47d59f06b6,
title = "Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells",
abstract = "Endothelial progenitor cells could be implicated in the aberrant neoangiogenesis that occurs in bone marrow and spleen in patients with primary myelofibrosis (PMF). However, antivascular endothelial growth factor (VEGF) monotherapy had only a modest and transient effect in these individuals. Recently it was found that VEGF-induced proangiogenic intracellular Ca2+ oscillations could be impaired in endothelial progenitor cells of subjects with malignancies. Therefore, we employed Ca2+ imaging, wavelet analysis, and functional assays to assess whether and how VEGF-induced Ca2+ oscillations are altered in PMF-derived endothelial progenitor cells. We focused on endothelial colony-forming cells (ECFCs), which are the only endothelial progenitor cell subtype capable of forming neovessels both in vivo and in vitro. VEGF triggers repetitive Ca2+ spikes in both normal ECFCs (N-ECFCs) and ECFCs obtained from PMF patients (PMF-ECFCs). However, the spiking response to VEGF is significantly weaker in PMF-ECFCs. VEGF-elicited Ca2+ oscillations are patterned by the interaction between inositol-1,4,5-trisphosphate-dependent Ca2+ mobilization and store-operated Ca2+ entry. However, in most PMF-ECFCs, Ca2+ oscillations are triggered by a store-independent Ca2+ entry pathway. We found that diacylglycerol gates transient receptor potential canonical 1 channel to trigger VEGF-dependent Ca2+ spikes by recruiting the phospholipase C/inositol-1,4,5-trisphosphate signaling pathway, reflected as a decrease in endoplasmic reticulum Ca2+ content. Finally, we found that, apart from being less robust and dysregulated as compared with N-ECFCs, VEGF-induced Ca2+ oscillations modestly stimulate PMF-ECFC growth and in vitro angiogenesis. These results may explain the modest effect of anti-VEGF therapies in PMF.",
author = "Silvia Dragoni and Marta Reforgiato and Estella Zuccolo and Valentina Poletto and Francesco Lodola and Ruffinatti, {Federico Alessandro} and Elisa Bonetti and Germano Guerra and Giovanni Barosi and Vittorio Rosti and Francesco Moccia",
year = "2015",
month = "5",
day = "19",
doi = "10.1016/j.exphem.2015.09.002",
language = "English",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Dysregulation of VEGF-induced proangiogenic Ca2+ oscillations in primary myelofibrosis-derived endothelial colony-forming cells

AU - Dragoni, Silvia

AU - Reforgiato, Marta

AU - Zuccolo, Estella

AU - Poletto, Valentina

AU - Lodola, Francesco

AU - Ruffinatti, Federico Alessandro

AU - Bonetti, Elisa

AU - Guerra, Germano

AU - Barosi, Giovanni

AU - Rosti, Vittorio

AU - Moccia, Francesco

PY - 2015/5/19

Y1 - 2015/5/19

N2 - Endothelial progenitor cells could be implicated in the aberrant neoangiogenesis that occurs in bone marrow and spleen in patients with primary myelofibrosis (PMF). However, antivascular endothelial growth factor (VEGF) monotherapy had only a modest and transient effect in these individuals. Recently it was found that VEGF-induced proangiogenic intracellular Ca2+ oscillations could be impaired in endothelial progenitor cells of subjects with malignancies. Therefore, we employed Ca2+ imaging, wavelet analysis, and functional assays to assess whether and how VEGF-induced Ca2+ oscillations are altered in PMF-derived endothelial progenitor cells. We focused on endothelial colony-forming cells (ECFCs), which are the only endothelial progenitor cell subtype capable of forming neovessels both in vivo and in vitro. VEGF triggers repetitive Ca2+ spikes in both normal ECFCs (N-ECFCs) and ECFCs obtained from PMF patients (PMF-ECFCs). However, the spiking response to VEGF is significantly weaker in PMF-ECFCs. VEGF-elicited Ca2+ oscillations are patterned by the interaction between inositol-1,4,5-trisphosphate-dependent Ca2+ mobilization and store-operated Ca2+ entry. However, in most PMF-ECFCs, Ca2+ oscillations are triggered by a store-independent Ca2+ entry pathway. We found that diacylglycerol gates transient receptor potential canonical 1 channel to trigger VEGF-dependent Ca2+ spikes by recruiting the phospholipase C/inositol-1,4,5-trisphosphate signaling pathway, reflected as a decrease in endoplasmic reticulum Ca2+ content. Finally, we found that, apart from being less robust and dysregulated as compared with N-ECFCs, VEGF-induced Ca2+ oscillations modestly stimulate PMF-ECFC growth and in vitro angiogenesis. These results may explain the modest effect of anti-VEGF therapies in PMF.

AB - Endothelial progenitor cells could be implicated in the aberrant neoangiogenesis that occurs in bone marrow and spleen in patients with primary myelofibrosis (PMF). However, antivascular endothelial growth factor (VEGF) monotherapy had only a modest and transient effect in these individuals. Recently it was found that VEGF-induced proangiogenic intracellular Ca2+ oscillations could be impaired in endothelial progenitor cells of subjects with malignancies. Therefore, we employed Ca2+ imaging, wavelet analysis, and functional assays to assess whether and how VEGF-induced Ca2+ oscillations are altered in PMF-derived endothelial progenitor cells. We focused on endothelial colony-forming cells (ECFCs), which are the only endothelial progenitor cell subtype capable of forming neovessels both in vivo and in vitro. VEGF triggers repetitive Ca2+ spikes in both normal ECFCs (N-ECFCs) and ECFCs obtained from PMF patients (PMF-ECFCs). However, the spiking response to VEGF is significantly weaker in PMF-ECFCs. VEGF-elicited Ca2+ oscillations are patterned by the interaction between inositol-1,4,5-trisphosphate-dependent Ca2+ mobilization and store-operated Ca2+ entry. However, in most PMF-ECFCs, Ca2+ oscillations are triggered by a store-independent Ca2+ entry pathway. We found that diacylglycerol gates transient receptor potential canonical 1 channel to trigger VEGF-dependent Ca2+ spikes by recruiting the phospholipase C/inositol-1,4,5-trisphosphate signaling pathway, reflected as a decrease in endoplasmic reticulum Ca2+ content. Finally, we found that, apart from being less robust and dysregulated as compared with N-ECFCs, VEGF-induced Ca2+ oscillations modestly stimulate PMF-ECFC growth and in vitro angiogenesis. These results may explain the modest effect of anti-VEGF therapies in PMF.

UR - http://www.scopus.com/inward/record.url?scp=84953283335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953283335&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2015.09.002

DO - 10.1016/j.exphem.2015.09.002

M3 - Article

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

ER -